Moreover, longitudinal AD studies have identified subjects with significant amyloid accumulation, but with largely absent neurite/synapse degeneration and/or cognitive impairment (termed AD resilience)2 and this has further stimulated interest in the identification of mechanistic targets and therapeutic approaches that might prevent degeneration promoted by the Aβ-tau axis. This evidence concerns the gene MAPT and Alzheimer disease.